Synta Announces Publication of Clinical and Non-Clinical Results Demonstrating Unique Anti-angiogenic Effects of Ganetespib

  Synta Announces Publication of Clinical and Non-Clinical Results
  Demonstrating Unique Anti-angiogenic Effects of Ganetespib

   – Results Suggest Targeting Hsp90 May Inhibit Angiogenesis without Tumor
  Rebound Effects Associated with VEGF-Targeted Anti-angiogenic Therapies –

  – Support Rationale for Combining Ganetespib with Standard Anti-angiogenic
                                   Agents –

Business Wire

LEXINGTON, Mass. -- July 17, 2013

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced today publication of
results from in vitro, in vivo, and translational clinical studies
demonstrating the effect of ganetespib on the ability of tumors to grow new
blood vessels (angiogenesis). The paper appeared in the July 10, 2013, online
issue of Angiogenesis. Ganetespib, a selective inhibitor of the Hsp90
chaperone protein in development by Synta, is being evaluated in over 20
clinical trials for different types of cancer, including a pivotal Phase 3
trial in non-small cell lung cancer.

“To date two therapeutic strategies have been established for inhibiting new
tumor blood vessel formation: agents that bind directly to vasculature growth
factors (e.g., VEGF), or agents that bind to their cellular receptors (e.g.,
VEGFR),” said Dr. Bassel El-Rayes, Director of the GI Oncology Translational
Research Program, Winship Cancer Institute, Emory University and senior author
of the paper. “The results published this week show that ganetespib may offer
a third way to suppress angiogenesis: inhibiting the transcription factors
that turn on production of VEGF and other pro-angiogenic factors. This is like
turning off the faucet at the source, rather than trying to empty the sink
once it is full.”

The publication describes results from preclinical studies and a rectal cancer
clinical trial conducted at Emory University showing that ganetespib
simultaneously downregulates the expression of many cellular proteins involved
in new blood vessel formation, including VEGF, PDGFA, FGF2, Ang-1, Ang-2,
TGFb1, HIF-1a, and STAT-3.

“Targeting angiogenesis with anti-VEGF therapies has demonstrated meaningful
clinical benefit, but has also been associated with greater disease
aggressiveness and metastasis from increased expression of VEGF-A and
activation of HIF-1a in the hypoxic tumor,” said Dr. El-Rayes. “These studies
show that the unique mechanism of action of ganetespib may provide a means to
downregulate angiogenesis without upregulating HIF-1a activation and VEGF
expression. These effects strongly support the rationale to combine ganetespib
with standard anti-angiogenic agents.”

Previously presented results showed synergistic activity of ganetespib and the
anti-angiogenic agent bevacizumab, an antibody targeting VEGF, in preclinical
models of cancer.

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of
heat shock protein 90 (Hsp90), a molecular chaperone which controls the
folding and activation of a number of client proteins that drive tumor
development and progression. Many solid and hematologic tumors are dependent
on Hsp90 client proteins including proteins involved in “oncogene addiction”
(ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2);
proteins involved in resistance to chemotherapy and radiation therapy (ATR,
BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in
angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in
metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical
models, inhibition of Hsp90 by ganetespib results in the inactivation,
destabilization, and eventual degradation of these cancer-promoting proteins.
Ganetespib is being evaluated in over 20 clinical trials including trials in
lung, breast, colorectal, and hematologic malignancies. Information on these
trials can be found at

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit

Safe Harbor Statement

This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified by the
use of forward-looking terminology such as "will", "would", "should",
"expects", "anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements, including statements relating to
the developments and progress of our clinical and preclinical programs,
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements, including those described in "Risk Factors" of our
Form 10-K for the year ended December 31, 2012 as filed with the Securities
and Exchange Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future events
or otherwise, except as required by law.


Investor Relations Contacts:
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
Argot Partners
Andrea Rabney, 212-600-1494
Press spacebar to pause and continue. Press esc to stop.